RTS-V5, a dual inhibitor that targets HDAC6 and the 20S subunit of the proteasome, also possesses potent and selective anti-tumor activity in leukemia and MM cell lines (Bhatia et al., 2018). This evidence concerns the gene HDAC6 and Miyoshi myopathy.